Hexarelin (Examorelin)

Hexarelin (also known as Examorelin) is a synthetic hexapeptide growth hormone releasing peptide (GHRP) and one of the most potent GH secretagogues studied. Derived from GHRP-6 by Mediolanum Farmaceutici, it stimulates growth hormone release through the ghrelin receptor (GHS-R1a) and uniquely binds to cardiac CD36 receptors, providing cardioprotective effects independent of GH release. Hexarelin reached Phase II clinical trials for growth hormone deficiency and congestive heart failure but was discontinued in 2005 for strategic reasons. Research demonstrates its potential in cardioprotection, neuroprotection, and metabolic regulation.

• Growth Hormone Release
• IGF-1 Elevation
• Pulsatile GH Pattern

Most potent GHRP for GH release, unique cardioprotective effects via CD36 receptor, supports tissue repair and recovery, neuroprotective properties

Binds to ghrelin receptor (GHS-R1a) on pituitary somatotrophs to stimulate pulsatile GH release. Also activates cardiac CD36 receptors providing GH-independent cardioprotection through anti-apoptotic and anti-fibrotic mechanisms.

Peak plasma concentration: 30 min. Elimination half-life: 1 hr. Largely cleared by: ~5 hrs.

Research protocols from published literature — not dosing recommendations.

• CJC-1295 (without DAC) — Synergistic: GHRP + GHRH combination provides complementary GH release through different receptor pathways. Studies show synergistic peak GH secretion rates greater than the arithmetic sum of isolated administration.
• Sermorelin — Synergistic: GHRH analog enhances hexarelin's pulsatile GH release. Research demonstrates synergistic effects when co-administered, though synergy diminishes with repeated dosing.
• Ipamorelin — Compatible: Both are GHRPs with different selectivity profiles. Combining may soften hexarelin's cortisol/prolactin elevation while maintaining GH output through complementary receptor activity.
• GHRP-6 — Use Caution: Both GHRPs stimulate GH through similar pathways. Combination may cause excessive GH spikes and additive side effects including cortisol and prolactin elevation.
• GHRP-2 — Use Caution: Structurally similar GHRPs with overlapping mechanisms. Combining provides diminishing returns with increased risk of hormonal side effects.
• CJC-1295 with DAC — Use Caution: DAC version provides continuous GH elevation which may conflict with hexarelin's pulsatile release pattern, potentially reducing synergistic benefits and accelerating desensitization.
• MK-677 — Monitor Combination: Both stimulate GH through ghrelin receptor. MK-677's continuous oral action combined with hexarelin may lead to excessive and prolonged GH elevation requiring monitoring.
• Tesamorelin — Synergistic: FDA-approved GHRH analog works through complementary pathway. Studies on GHRH + hexarelin combinations show synergistic GH release significantly greater than either alone.
• HGH — Avoid Combination: Exogenous HGH suppresses natural GH release pathways. Combining defeats hexarelin's purpose and may cause excessive GH levels with increased side effects.
• BPC-157 — Compatible: Different mechanisms with no known interactions. BPC-157's tissue repair properties may complement hexarelin's recovery and cardioprotective effects.

Supplies:

• Hexarelin lyophilized powder vial (typically 2mg or 5mg)
• Bacteriostatic water (2mL per 2mg vial)
• Insulin syringes (29-31 gauge)
• Alcohol prep pads
• Sterile mixing needle (optional)

1. 1Clean both vial tops with alcohol and let dry completely
2. 2For 2mg vial: Add 2mL bacteriostatic water (creates 100mcg per 10 units)
3. 3For 5mg vial: Add 2.5mL bacteriostatic water (creates 200mcg per 10 units)
4. 4Inject water slowly down the side of the vial to prevent foaming
5. 5Gently swirl or roll vial - do not shake vigorously
6. 6Solution should be clear and colorless
7. 7Label with reconstitution date and concentration
8. 8Store immediately in refrigerator at 2-8°C

Day 1-7: Improved sleep quality, potential facial flushing post-injection, increased appetite possible. Week 2-4: Enhanced recovery from exercise, improved skin quality, beginning of body composition changes. Week 4-8: Noticeable improvements in lean mass and fat loss, some desensitization may begin. Week 8-12: Continued benefits but GH response reduced 40-50% from baseline. Week 12-16: Maximum cycle length - take mandatory 4-6 week break to restore sensitivity. Post-cycle: GH response recovers to near-baseline within 4 weeks off.

Most potent GHRP but also highest side effect profile among GHRPs. Elevates cortisol and prolactin at standard doses - unlike Ipamorelin. May cause water retention, particularly in first 1-2 weeks. Can affect glucose metabolism - monitor if diabetic or pre-diabetic. Not recommended for those with active cancer due to growth-promoting effects. WADA prohibited substance - banned in competitive sports. Secondary hypogonadism possible with prolonged use due to prolactin elevation. Partial desensitization is normal and reversible with cycling.

Most potent GHRP but also highest side effect profile among GHRPs. Elevates cortisol and prolactin at standard doses - unlike Ipamorelin. May cause water retention, particularly in first 1-2 weeks. Can affect glucose metabolism - monitor if diabetic or pre-diabetic. Not recommended for those with active cancer due to growth-promoting effects. WADA prohibited substance - banned in competitive sports. Secondary hypogonadism possible with prolonged use due to prolactin elevation. Partial desensitization is normal and reversible with cycling.

Hexarelin (Examorelin) should be stored at Refrigerate at 2-8°C immediately after reconstitution. Use within 4 weeks..